Identification of Potential Prognostic Biomarkers for Sorafenib Efficacy in Hepatocellular Carcinoma Cells by Proteomic Approaches
碩士 === 國立臺灣大學 === 生物化學暨分子生物學研究所 === 105 === Hepatocellular carcinoma, HCC, is the most common liver cancer in the world. Clinically, there are many biomarkers which can be used to diagnose HCC and predict prognosis. According to the Barcelona-clinic liver cancer staging (BCLC staging), sorafenib is...
Main Authors: | Ming Jiun Tsai, 蔡銘駿 |
---|---|
Other Authors: | Lu-Ping Chow |
Format: | Others |
Language: | zh-TW |
Published: |
2017
|
Online Access: | http://ndltd.ncl.edu.tw/handle/uxbqfs |
Similar Items
-
Integrated Proteomics and Bioinformatics to Identify Potential Prognostic Biomarkers in Hepatocellular Carcinoma
by: Zhang Q, et al.
Published: (2021-03-01) -
Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
by: Khaldoun Almhanna, et al.
Published: (2009-11-01) -
Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib
by: Alessandro Granito, et al.
Published: (2016-03-01) -
Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma.
by: Sangheun Lee, et al.
Published: (2013-01-01) -
Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.
by: Ming-Han Hsieh, et al.
Published: (2020-01-01)